Skip to content
‹ Back to IndustriesHealthcare

DESIGN TRANSFER: A PROCESS NOT A SINGULAR EVENT

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process.

During the product development process, the Research and Development (R&D) team is under a tight deadline. They may not have the necessary resources or take sufficient time to create proper documentation. Team members may need to make decisions quickly without fully considering how they could take proactive steps to ensure design transfer will go more smoothly. Subject matter experts on the team may only focus on critical design decisions required to make the product work, without regard for manufacturing. Let’s take a look at some ways to improve design transfer.

Look at Design Transfer as a Process Rather than a Single Event

Design transfer is an integral part of the product development process, from conception through final manufacture. Highly reliable, cost-efficient medical devices require proper design transfer, and that starts with Design for Manufacturability (DFM) and Design for Manufacturing and Assembly (DFMA). In DFM and DFMA the focus is not only on the design itself, but also on the assembly method, ensuring manufacturing readiness for building Beta units, pre-production clinical units, and the pilot program. When the R&D team considers these factors and performs in-process testing, it can significantly improve product quality and reduce the overall cost of manufacturing.

Using DFMA 

The goal of DFMA is simple: to transfer product design into viable, robust production methods. To succeed, the team must establish and maintain procedures that ensure the device design translates into production specifications, including final test acceptance. The transfer should negate and/or identify remaining risks such as single-sourcing, long lead items, build timelines, and line/tooling capacity.

A Design Ready for Transfer:

  • Can be built reliably using known and proven manufacturing and assembly processes
  • Includes supporting cell/line qualifications through manufacturing validations such as Operational Qualification (OQ) and Performance Qualification (PQ)
  • Specifies and documents any inspection aids, assembly fixtures, and custom tools required for manufacture
  • Confirms completed agency testing and production target hardware meets regulatory requirements such as FDA, UL, and CE
  • Includes a complete product Bill of Material (BOM) that has been fully costed up to the customer Stock Keeping Unit (SKU) level
  • Includes packaging, labeling, and Instructions for Use (IFU)

At Sunrise Labs, we see Design Transfer as an integral process beginning early in the life of a product with many crucial steps for success. Communication between key stakeholders early and often is critical to turn innovative ideas into commercial medical devices.

Read more at sunriselabs.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

AI cuts cardiologists' echocardiogram review time by 46%

AI cuts cardiologists' echocardiogram review time by 46%

Late-breaking research presented November 9 at the American Heart Association's Scientific Sessions 2026 reported that AI-drafted preliminary echocardiogram reports were comparable to human drafts. Cardiologists averaged 4.6 minutes finalizing AI drafts versus 8.5 minutes without AI. The findings are a non-peer-reviewed abstract.

  • 01Cardiologists averaged 4.6 minutes finalizing AI-drafted echo reports versus 8.5 minutes without AI, about 46% less time.
  • 02Cardiologists made substantial changes to 50.6% of AI drafts and 49.7% of human drafts.
  • 03The research used 1,200 echocardiograms from 21 Kaiser Permanente Northern California medical centers.

Nov 9, 2026

After Chicago: Did AI at AHA 2026 Pass Its Own Test?

After Chicago: Did AI at AHA 2026 Pass Its Own Test?

At AHA Scientific Sessions 2026 in Chicago, AI ECHO INSIGHT, WATCH-LV, PARAMOUNT and PROVAR+ showed gains in workflow efficiency, screening and treatment decisions, but none established a reduction in hard clinical events. The takeaway: the next test is proving these tools improve outcomes, especially in high-need populations, by connecting to established care.

  • 01AI ECHO INSIGHT cut echo reads 8.5 to 4.6 minutes, and PARAMOUNT changed treatment decisions, but no AI late-breaker showed fewer hard events.
  • 02ZEUS and Lp(a)HORIZON lowered their target biomarkers without reducing major cardiovascular events, a caution against treating algorithmic accuracy alone as proof of patient benefit.
  • 03Low-technology, team-based interventions such as CATCH in Colombia and Jamaica lowered blood pressure, showing the care systems AI tools must connect to.

Nov 9, 2026

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Access TeleCare pharmacist Ashley Selby describes a telehealth antimicrobial stewardship model sized to each hospital's gaps. Joint Commission Standard MM.09.01.01 and 42 CFR 482.42 require a qualified physician and/or pharmacist leader, not a full-time hire, and a 14-study meta-analysis found telehealth stewardship cut antibiotic days of therapy without changing mortality.

  • 01Joint Commission Standard MM.09.01.01, in force since January 2023, requires a physician and/or pharmacist qualified in infectious diseases or stewardship to lead the program, and its committee note allows remote participation.
  • 02The Board of Pharmacy Specialties counts more than 2,380 BCIDP pharmacists nationally, while many small hospitals still assign stewardship to pharmacists without ID training.
  • 03A 14-study meta-analysis found telehealth stewardship raised guideline adherence and cut antibiotic days of therapy, but did not significantly change mortality.

Nov 9, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512